Social Media Ideas for Phase 3 Trial

Latest updates for Phase 3 Trial

Fresh curated links around Phase 3 trial are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

newswire.com /1 month ago

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline A...

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses

Read source

psychedelicalpha.com /1 week ago

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD). The data are from Part B of COMP006...

Read source

fiercebiotech.com /2 days ago

CEPI-backed Ebola vaccine set to enter phase 1 trials

The first vaccine against the Bundibugyo ebola virus is poised to enter phase 1 clinical trial.

Read source

parkinsonsnewstoday.com /1 month ago

Phase 2a trial of Jotrol for Parkinson’s begins enrolling patients in the U.S.

Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s...

Read source

parkinsonsnewstoday.com /5 days ago

Trial of fast-tracked new Parkinson’s cell therapy hits ‘critical’ step

Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasinep...

Read source

medcitynews.com /6 days ago

Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market

AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared...

Read source

fiercebiotech.com /4 weeks ago

F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test

F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.

Read source

qchron.com /1 day ago

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-...

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the supe...

Read source

webwire.com /1 month ago

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achiev...

- - • Data from the head-to-head study show efdoralprin alfa normalized and maintained functional AAT levels in people living with alpha-1 antitrypsin deficiency - • Efdoralpr...

Read source

fiercebiotech.com /1 month ago

Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment

Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients...

Read source

fiercebiotech.com /3 weeks ago

Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision

A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch...

Read source

parkinsonsnewstoday.com /2 days ago

Small US trial of Parkinson’s cell therapy hits ‘important milestone’

Kenai Therapeutics has completed patient enrollment in a small, early clinical trial testing the safety and effectiveness of RNDP-001, its direct-to-the-brain cell therapy for trea...

Read source

biopharmadive.com /1 month ago

Kailera’s three-pronged obesity shot shows promise in early trial

As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

Read source

fiercebiotech.com /2 weeks ago

Vistagen fails another phase 3 social anxiety trial but spies path to market

Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial. But, with a post hoc subpopulation analysis linking fasedienol to a nominally statistically sig...

Read source

parkinsonsnewstoday.com /1 month ago

Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy

Topline results from a Phase 2 trial testing oral bezisterim as a first-line, stand-alone treatment for early Parkinson’s disease are expected later this year following the complet...

Read source

parkinsonsnewstoday.com /1 month ago

VT-5006 oral therapy advances into Phase 1b testing for Parkinson’s disease

The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Park...

Read source

multiplesclerosisnewstoday.com /1 month ago

Enrollment in MS imaging study reaches halfway mark

Enrollment is half complete in an ongoing clinical study at Massachusetts General Hospital (MGH) testing whether a PET imaging tracer can reliably measure myelin damage in people w...

Read source

qchron.com /1 month ago

Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II s...

HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative ther...

Read source

bioengineer.org /1 month ago

World’s First Phase 3 Trial of In Vivo CRISPR Therapy Successfully Concludes, Bringing CRISPR Treatment Closer to Realit...

In a groundbreaking advancement that sets a new paradigm in genetic medicine, researchers at Amsterdam University Medical Center (Amsterdam UMC), collaborating with several interna...

Read source

multiplesclerosisnewstoday.com /1 month ago

Trial of foralumab nasal spray for nonactive SPMS fills up

Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (...

Read source

fiercebiotech.com /2 weeks ago

Evommune’s phase 2b trial flops, ending challenge to Novartis in hives

A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for the chronic spontaneous urticaria market.

Read source

fiercebiotech.com /1 day ago

Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...

Read source

prweb.com /2 weeks ago

Major Biopharmaceutical Company Files First-in-Human Trial Supported by PAK BioSolutions GMP Purification System

A major biopharmaceutical company has filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system. The milestone demons...

Read source

multiplesclerosisnewstoday.com /2 weeks ago

Nasal MS therapy moves closer to results after final patient dosed

A Phase 2a clinical trial testing Tiziana Life Sciences‘ experimental intranasal therapy foralumab in people with nonactive secondary progressive multiple sclerosis (SPMS) has begu...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.